3D printing and nanotechnology have been two important tools in the development of therapeutic approaches for personalized medicine. More recently, their alliance has been improved in an effort to build innovative, versatile, multifunctional, and/or smart medical and pharmaceutical products. Therefore, an extensive review about scientific studies that ally 3D printing and nanomaterials in the development of new approaches for pharmaceutical and medical applications for the treatment and prevention of diseases is presented here. The articles are classified into five categories according to their main application: Cell growth and tissue engineering, antimicrobial, drug delivery, stimulus‐response, and theranostics. Semisolid extrusion, inorganic nanoparticles, and cell growth and tissue engineering are the most reported 3D printing technique, type of nanomaterial, and application, respectively. The increase in papers dedicated to these areas is also notable, especially in the 2019 and 2020, when semisolid extrusion became the most used technique, overcoming fused deposition modelling. In fact, this review highlights that the possibility of an alliance between 3D printing and nanotechnology for the production of multiscale materials is undoubtedly a great opportunity for knowledge and innovation in the pharmaceutical and medical area.

Eudragit® polymers are polymethacrylates highly used in pharmaceutics for the development of modified drug delivery systems. They are widely known due to their versatility with regards to chemical composition, solubility, and swelling properties. Moreover, Eudragit polymers are thermoplastic, and their use has been boosted in some production processes, such as hot melt extrusion (HME) and fused deposition modelling 3D printing, among other 3D printing techniques. Therefore, this review covers the studies using Eudragit polymers in the development of drug delivery systems produced by HME and 3D printing techniques over the last 10 years. Eudragit E has been the most used among them, mostly to formulate immediate release systems or as a taste-masker agent. On the other hand, Eudragit RS and Eudragit L100-55 have mainly been used to produce controlled and delayed release systems, respectively. The use of Eudragit polymers in these processes has frequently been devoted to producing solid dispersions and/or to prepare filaments to be 3D printed in different dosage forms. In this review, we highlight the countless possibilities offered by Eudragit polymers in HME and 3D printing, whether alone or in blends, discussing their prominence in the development of innovative modified drug release systems.

No abstract

No abstract

No abstract